Manages spasticity. ANDA 210267, held by Ingenus Pharmaceuticals. Tizanidine Hydrochloride.
As of Nov 21, 2026, ANDA 210267 (Tizanidine Hydrochloride), held by Ingenus Pharmaceuticals, was first approved by FDA on Mar 12, 2019, with 2 approved supplements and 0 published complete response letters.
Tizanidine hydrochloride is indicated for the management of spasticity. Because of the short duration of therapeutic effect, treatment with tizanidine hydrochloride capsules should be reserved for those daily activities and times when relief of spasticity is most important.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 12, 2019 | Original application | Approved | None posted |
| Tizanidine HydrochlorideEQ 2MG BASE · capsule;oral | Tizanidine Hydrochloride | Rx |
| Tizanidine HydrochlorideEQ 4MG BASE · capsule;oral | Tizanidine Hydrochloride | Rx |
| Tizanidine HydrochlorideEQ 6MG BASE · capsule;oral | Tizanidine Hydrochloride | Rx |
| Sep 29, 2025 | Supplement 4Labeling · Standard review | Approved | None posted |
| May 27, 2022 | Supplement 2Labeling · Standard review | Approved | None posted |
| Mar 12, 2019 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters